Iron deficiency in heart failure: A practical guide

Nutrients

Volumn 5, Issue 9, 2013, Pages 3730-3739

  Ebner, Nicole ^a   von Haehling, Stephan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anaemia; Heart failure; Iron deficiency; Metabolism

Indexed keywords

ANTIANEMIC AGENT; ENZYME; FERRIC CARBOXYMALTOSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON SACCHARATE; IRON SUCCINATE; MYOGLOBIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANEMIA; CARDIOVASCULAR DISEASE; COMORBIDITY; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; ELECTRON TRANSPORT; HEART FAILURE; HUMAN; IRON DEFICIENCY; IRON METABOLISM; OXYGEN TRANSPORT; PREVALENCE; REVIEW; SYMPTOM; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; HEART FAILURE; HUMANS; IRON; PREVALENCE;

EID: 84884578679     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu5093730     Document Type: Review

References (48)

1. Jelani, Q.U.; Katz, S.D. Treatment of anemia in heart failure: Potential risks and benefits of intravenous iron therapy in cardiovascular disease. Cardiol. Rev. 2010, 18, 240-250.
2. Toblli, J.E.; Silverberg, D.S.; di Gennaro, F.; Duarte, P.; Facchini, M.; Angerosa, M. Iron Metabolism. In Cardio-Renal Anaemia Syndrome CRAS Basics and Clinical Aspects, 1st ed.; Publicaciones Latinoamericanas: Buenos Aires, Argentina, 2008.
3. Okonko, D.O.; Mandal, A.K.; Missouris, C.G.; Poole-Wilson, P.A. Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival. J. Am. Coll. Cardiol. 2011, 58, 1241-1251.
4. Klip, I.T.; Comin-Colet, J.; Voors, A.A.; Ponikowski, P.; Enjuanes, C.; Banasiak, W.; Lok, D.J.; Rosentryt, P.; Torrens, A.; Polonski, L.; et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am. Heart J. 2013, 165, 575-582.
5. Jankowska, E.A.; von Haehling, S.; Anker, S.D.; Macdougall, I.C.; Ponikowski, P. Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives. Eur. Heart J. 2013, 34, 816-829.
6. Groenveld, H.F.; Januzzi, J.L.; Damman, K.; van Wijngaarden, J.; Hillege, H.L.; van Veldhuisen, D.J.; van der Meer, P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J. Am. Coll. Cardiol. 2008, 52, 818-827.
7. Jankowska, E.A.; Malyszko, J.; Ardehali, H.; Koc-Zorawska, E.; Banasiak, W.; von Haehling, S.; Macdougall, I.C.; Weiss, G.; McMurray, J.J.; Anker, S.D.; et al. Iron status in patients with chronic heart failure. Eur. Heart J. 2013, 34, 827-834.
8. Anker, S.D.; Colet, J.C.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Lüscher, T.F.; Bart, B.; Banasiak, W.; Niegowska, J.; et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 2009, 361, 2436-2448.
9. Ezekowitz, J.A.; McAlister, F.A.; Armstrong, P.W. Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003, 107, 223-225.
10. Tsung, S.H.; Rosenthal, W.A.; Milewski, K.A. Immunological measurement of transferrin compared with chemical measurement of total iron-binding capacity. Clin. Chem. 1975, 21, 1063-1066.
11. von Haehling, S.; Anker, S.D. Iron Deficiency in Health and Disease. In Anaemia in Chronic Heart Failure, 2nd ed.; Anker, S.D., von Haehling, S., Eds.; UNI-MED Verlag AG: Bremen, Germany, 2009.
12. Cohen, L.A.; Gutierrez, L.; Weiss, A.; Leichtmann-Bardoogo, Y.; Zhang, D.; Crooks, D.R.; Sougrat, R.; Morgenstern, A.; Galy, B.; Hentze, M.W.; et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 2010, 116, 1574-1584.
13. Anderson, G.J.; Vulpe, C.D. Mammalian iron transport. Cell. Mol. Life Sci. 2009, 66, 3241-3261.
14. Ye, H.; Rouault, T.A. Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease. Biochemistry 2010, 49, 4945-4956.
15. Schultz, I.J.; Chen, C.; Paw, B.H.; Hamza, I. Iron and porphyrin trafficking in heme biogenesis. J. Biol. Chem. 2010, 285, 26753-26759
16. Richardson, D.R.; Lane, D.J.; Becker, E.M.; Huang, M.L.; Whitnall, M.; Suryo Rahmanto, Y.; Sheftel, A.D.; Ponka, P. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc. Natl. Acad. Sci. USA 2010, 107, 10775-10782.
17. Oudit, G.Y.; Sun, H.; Trivieri, M.G.; Koch, S.E.; Dawood, F.; Ackerley, C.; Yazdanpanah, M.; Wilson, G.J.; Schwartz, A.; Liu, P.P.; Backx, P.H. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med. 2003, 9, 1187-1194.
18. Murphy, C.J.; Oudit G.Y. Iron-overload cardiomyopathy: Pathophysiology, diagnosis, and treatment. J. Card. Fail. 2010, 16, 888-900.
19. Glaspy, J.; Cavill, I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology (Williston Park) 1999, 13, 461-473.
20. Eschbach, J.W.; Egrie, J.C.; Downing, M.R.; Browne, J.K.; Adamson, J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987, 316, 73-78.
21. Van Veldhuisen, D.J.; Anker, S.D.; Ponikowski, P.; Macdougall, I.C. Anemia and iron deficiency in heart failure: Mechanisms and therapeutic approaches. Nat. Rev. Cardiol. 2011, 8, 485-493.
22. Kapoor, M.; Schleinitz, M.D.; Gemignani, A.; Wu, W.C. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: A meta-analysis. Cardiovasc. Hematol. Disord. Drug Targets 2012, 13, 35-44.
23. Jankowska, E.A.; Rozentryt, P.; Witkowska, A.; Nowak, J.; Hartmann, O.; Ponikowska, B.; Borodulin-Nadzieja, L.; Banasiak, W.; Polonski, L.; Filippatos, G.; et al. Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur. Heart J. 2010, 31, 1872-1880.
24. Punnonen, K.; Irjala, K.; Rajamäki, A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997, 89, 1052-1057.
25. Leszek, P.; Sochanowicz, B.; Szperl, M.; Kolsut, P.; Brzóska, K.; Piotrowski, W.; Rywik, T.M.; Danko, B.; Polkowska-Motrenko, H.; Różański, J.M.; et al. Myocardial iron homeostasis in advanced chronic heart failure patients. Int. J. Cardiol. 2012, 159, 47-52.
26. Koury, S.T.; Bondurant, M.C.; Koury, M.J. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988, 71, 524-527.
27. Lacombe, C.; da Silva, J.L.; Bruneval, P.; Fournier, J.G.; Wendling, F.; Casadevall, N.; Camilleri, J.P.; Bariety, J.; Varet, B.; Tambourin, P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J. Clin. Investig. 1988, 81, 620-623.
28. Handelman, G.J.; Levin, N.W. Iron and anemia in human biology: A review of mechanisms. Heart Fail. Rev. 2008, 13, 393-404.
29. Willis, W.T.; Gohil, K.; Brooks, G.A.; Dallman, P.R. Iron deficiency: Improved exercise performance within 15 h of iron treatment in rats. J. Nutr. 1990, 120, 909-916.
30. Tobin, B.W.; Beard, J.L. Interactions of iron deficiency and exercise training relative to tissue norepinephrine turnover, triiodothyronine production and metabolic rate in rats. J. Nutr. 1990, 120, 900-908.
31. Blayney, L.; Bailey-Wood, R.; Jacobs, A.; Henderson, A.; Muir, J. The effects of iron deficiency on the respiratory function and cytochrome content of rat heart mitochondria. Circ. Res. 1976, 39, 744-748.
32. Kroot, J.J.C.; Tjalsma, H.; Fleming, R.E.; Swinkels, D.W. Hepcidin in human iron disorders: Diagnostic implications. Clin. Chem. 2011, 57, 1650-1669.
33. Geisser, P. Safety and efficacy of iron(III)-hydroxide polymaltose complex/a review of over 25 years experience. Arzneimittelforschung 2007, 57, 439-452.
34. Silverberg, D.S.; Iaina, A.; Schwartz, D.; Wexler, D. Intravenous iron in heart failure: Beyond targeting anemia. Curr. Heart Fail. Rep. 2011, 8, 14-21.
35. Wish, J.B. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol. 2006, 1, S4-S8.
36. Feelders, R.A.; Kuiper-Kramer, E.P.; van Eijk, H.G. Structure, function and clinical significance of transferrin receptors. Clin. Chem. Lab. Med. 1999, 37, 1-10.
37. Aung, N.; Ling, H.Z.; Cheng, A.S.; Aggarwal, S.; Flint, J.; Mendonca, M.; Rashid, M.; Kang, S.; Weissert, S.; Coats, C.J.; et al. Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. Int. J. Cardiol. 2013, doi:10.1016/j.ijcard.2012.12.091.
38. Silverstein, S.B.; Rodgers, G.M. Parenteral iron therapy options. Am. J. Hematol. 2004, 76, 74-78.
39. Fishbane, S.; Kowalski, E. The comparative safety of intravenous iron dextran, iron saccharate and sodium ferric gluconate. Semin. Dial. 2000, 13, 381-384.
40. von Haehling, S.; Anker, S.D. Therapeutic Possibilities. In Anaemia in Chronic Heart Failure, 2nd ed.; Anker, S.D., von Haehling, S., Eds.; UNI-MED Verlag AG: Bremen, Germany, 2009.
41. Moore, R.A.; Gaskell, H.; Rose, P.; Allan, J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011, 11, 4.
42. Okonko, D.O.; Grzeslo, A.; Witkowski, T.; Mandal, A.K.; Slater, R.M.; Roughton, M.; Foldes, G.; Thum, T.; Majda, J.; Banasiak, W.; et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 2008, 51, 103-112.
43. Toblli, J.E.; Silverberg, D.S.; di Gennaro, F.; Duarte, P.; Facchini, M.; Angerosa, M. Treatment of Anaemia with Iron. In Cardio-Renal Anaemia Syndrome CRAS Basics and Clinical Aspects, 1st ed.; Publicaciones Latinoamericanas: Buenos Aires, Argentina, 2008.
44. Danielson, B.G. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am. Soc. Nephrol. 2004, 15, S93-S98.
45. Comín-Colet, J.; Enjuanes, C.; González, G.; Torrens, A.; Cladellas, M.; Meroño, O.; Ribas, N.; Ruiz, S.; Gómez, M.; Verdú, J.M.; et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur. J. Heart Fail. 2013, doi: 10.1093/eurjhf/hft083.
46. Ganzoni, A.M. Intravenous iron-dextran: Therapeutic and experimental possibilities. Schweiz. Med. Wochenschr. 1970, 100, 301-303 (in German).
47. Intravenous Iron in Patients with Severe Chronic Heart Failure and Chronic Kidney Disease. Available online: http://www.clinicaltrials.gov/ct2/show/NCT00384657 (accessed on 2 April 2013).
48. Iron Supplementation in Heart Failure Patients with Anemia: The IRON-HF Study. Available online: http://www.clinicaltrials.gov/ct2/show/NCT00386126 (accessed on 2 April 2013).